drugset / Trial / NCT06942767
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the first-line treatment of CLDN18.2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Timeline
- Start
- 2025-06
- Primary completion
- 2026-12
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL2107 | Unknown | — | — |
| Subject | QLS31905 | Unknown | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |